CIP2A and prostate cancer: In prostate cancer, autoAb-recognized prostate cancer-associated antigens (PCAA) may be divided into two categories: 1) autoAb recognize α-methylacyl-CoA (AMACR) [3,4], p90 autoantigen [5], and lens epithelium-derived growth factor p75 (LEDGF) [6], which have low levels of expression in normal tissues, but are overexpressed in prostate cancer; 2) autoAb react against cancer/testis antigens such as NY-ESO-1 [7], SSX-2,4 [8], and XAGE-1b [9], which are observed only in cancer patients but not healthy donors (HD) or patients with benign conditions.